149 related articles for article (PubMed ID: 3103382)
1. Critical role of MAO inhibition in Parkinson's disease.
Knoll J
Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
[No Abstract] [Full Text] [Related]
2. MAO-B inhibitors in Parkinson's disease.
Olanow CW
Adv Neurol; 1993; 60():666-71. PubMed ID: 8420207
[No Abstract] [Full Text] [Related]
3. MAO type B inhibitors as adjunct to L-dopa therapy.
Youdim MB; Finberg JP
Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
[No Abstract] [Full Text] [Related]
4. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
6. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
7. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
Fernandez HH; Chen JJ
Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
[TBL] [Abstract][Full Text] [Related]
8. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
9. [On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].
Kassubek J; Büttner T; Reichmann H; Riederer P; Schulz JB; Wüllner U; Csoti I
Fortschr Neurol Psychiatr; 2010 Mar; 78 Suppl 1():S34-6. PubMed ID: 20195940
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of the effects of isatin, an endogenous MAO-inhibitor, and selegiline on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by the Japanese encephalitis virus.
Hamaue N; Minami M; Terado M; Hirafuji M; Endo T; Machida M; Hiroshige T; Ogata A; Tashiro K; Saito H; Parvez SH
Neurotoxicology; 2004 Jan; 25(1-2):205-13. PubMed ID: 14697895
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Parkinson's disease.
Eadie MJ
Aust Fam Physician; 1995 Sep; 24(9):1685-7, 1690-2. PubMed ID: 7487655
[TBL] [Abstract][Full Text] [Related]
12. New mechanisms of action of irreversible monoamine oxidase type B inhibitors.
Li XM; Juorio AV; Paterson IA; Boulton AA
J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757
[No Abstract] [Full Text] [Related]
13. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
Müller T; Riederer P; Grünblatt E
J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease.
Imke S
Adv Nurse Pract; 1998 Jan; 6(1):24-8. PubMed ID: 9495941
[No Abstract] [Full Text] [Related]
15. [Neuroprotective and neurorestorative therapy in Parkinson's disease].
Jiménez-Jiménez FJ; Molina JA
Rev Neurol; 1997 Aug; 25 Suppl 2():S185-93. PubMed ID: 9280687
[TBL] [Abstract][Full Text] [Related]
16. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Tetrud JW; Langston JW
J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
[TBL] [Abstract][Full Text] [Related]
17. The pathobiology of Parkinson's disease: biochemical aspects of dopamine neuron senescence.
Cohen G
J Neural Transm Suppl; 1983; 19():89-103. PubMed ID: 6321651
[TBL] [Abstract][Full Text] [Related]
18. R-(-)-deprenyl and parkinsonism.
Yahr MD
J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
[TBL] [Abstract][Full Text] [Related]
19. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
20. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
[No Abstract] [Full Text] [Related]
[Next] [New Search]
